Two phosphAte taRGets in End-stage Renal Disease Trial (TARGET)

PHASE2CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
End-stage Renal Disease
Interventions
DRUG

Calcium carbonate ( Intensive phosphate control)

Individuals randomized to this arm will be exposed to a treatment strategy that targets a P of \< 1.50 mmol/L, reflecting the recommendations of current guidelines. Titration of the calcium carbonate dose will be the core of this approach and this will be complemented by usual recommendations regarding dietary P restriction. Dietitians will be available to provide counseling with regards to any aspect of the end-stage renal disease diet, as per usual dialysis unit practice

DRUG

Calcium carbonate (Liberalized phosphate control)

"Individuals in this arm will be exposed to a treatment strategy that allows P to rise above 2.00 mmol/L. This will be accomplished through structured reduction of P binders already in use (as per the algorithm detailed below). Rescue P binding will be instituted if P rises above 2.50 mmol/L. Dietitians will be available to provide counseling regarding any aspect of the end-stage renal disease diet, as per usual dialysis unit practice, but will not provide counseling on dietary P restriction unless the P rises above 2.50 mmol/L."

Trial Locations (5)

T2N 2T9

Foothills Medical Centre, Calgary

B3H 1V7

Capital District Health Authority, Halifax

L8N 4A6

St. Joseph's Healthcare, Hamilton

N6G 2V4

London Health Sciences Centre, London

M5B 1W8

St. Michael's Hospital, Toronto

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

Unity Health Toronto

OTHER

NCT01994733 - Two phosphAte taRGets in End-stage Renal Disease Trial (TARGET) | Biotech Hunter | Biotech Hunter